Table 2.

Univariate and multivariate analyses for factors associated with overall survival.

	Total (events)	Median (95% CI)	p value	HR (95% CI)	p value
Age (yr)			0.43
<65	455 (62)	83.6 (79.6–87.5)
≥65	185 (29)	77.3 (69.2–85.3)
Sex			0.271
Female	319 (39)	84.9 (80.1–89.6)
Male	321 (52)	79.4 (74.1–84.6)
pTNM stage			<0.001		0.001
I	75 (0)	No events		10.616 (2.480–45.441)
II	276 (22)	90.6 (86.4–94.7)
III	289 (69)	68.5 (61.-75.1)
Tumor differentiation			<0.001		0.086
Well and moderate	483 (58)	85.6 (81.8–89.3)		1.227 (0.972–1550)
Poor	157 (33)	69.0 (59.2–78.8)
Lymphovascular invasion			<0.001		0.188
No	421 (42)	87.7 (83.9–91.4)		1.381 (0.854–2.235)
Yes	219 (49)	71.0 (63.5–78.4)
Perineural invasion			<0.001		0.115
No	523 (63)	85.0 (81.2–88.7)		1.489 (0.907–2.443)
Yes	117 (28)	67.6 (56.8–78.3)
CCI			0.211
0	180 (23)	85.8 (80.1–91.7)
≥I	460 (68)	80.3 (75.7–84.8)
Cancer obstruction			0.047		0.110
No	562 (72)	83.7 (79.9–87.4)		1.532 (0.908–2.583)
Yes	78 (19)	72.4 (61.4–83.3)
Cancer perforation			0.123
No	583 (79)	83.1 (79.3–86.8)
Yes	57 (12)	74.1 (57.1–86.5)
Number of resected lymph nodes			0.303
<12	95 (18)	78.4 (69.1–87.6)
≥12	545 (73)	82.8 (78.8–86.7)
Pathology N stage			<0.001		0.082
N negative	357 (23)	92.4 (89.1–95.7)		0.268 (0.061–1.182)
N positive	283 (68)	69.4 (62.9–75.9)
Surgical margins/type of resection			0.009		0.041
R0	626 (86)	82.9 (79.4–86.4)		2.619 (1.039–6.599)
R1/R2	14 (5)	45.0 (09.5–80.5)
HALP score			0.013		0.031
<15	162 (31)	73.5 (64.9–82.1)		1.942 (1.647–2.875)
≥15.0	477 (60)	84.8 (80.5–89.1)

HALP: hemoglobin (g/L) × albumin (g/L) × lymphocytes (/L)/platelets (/L), BMI: body mass index, pTNM: pathological tumor-node-metastasis stage, CCI: Charlson comorbidity index.